ExodusPoint Capital Management’s Castle Biosciences CSTL Stock Holding History

ExodusPoint Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$801K	Buy	+32,608	New	+$1.07M	0.01%	1055
2025 Q2	–	Sell	-77,563	Closed	-$1.55M	–	1550
2025 Q1	$1.55M	Buy	77,563 +66,079	+575%	+$1.64M	0.02%	792
2024 Q4	$306K	Sell	11,484 -32,779	-74%	-$998K	﹤0.01%	1272
2024 Q3	$1.26M	Buy	44,263 +4,128	+10%	+$105K	0.01%	903
2024 Q2	$874K	Buy	+40,135	New	+$894K	0.01%	1067
2023 Q3	–	Sell	-63,773	Closed	-$875K	–	1772
2023 Q2	$875K	Buy	63,773 +41,292	+184%	+$837K	0.01%	1154
2023 Q1	$511K	Buy	+22,481	New	+$549K	﹤0.01%	1331
2020 Q3	–	Sell	-5,857	Closed	-$221K	–	1826
2020 Q2	$221K	Buy	+5,857	New	+$200K	0.01%	1462

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's CSTL Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Castle Biosciences (CSTL) in Q1 2026: 32,608 shares worth $801K. The stake represents 0.01% of the portfolio and ranks #1055 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in CSTL as recently as Q1 2025.

ExodusPoint Capital Management first reported a position in CSTL in Q2 2020 and has held it in 8 quarters since. The position peaked at $1.55M in Q1 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

ExodusPoint Capital Management held 32,608 shares of Castle Biosciences worth $801K as of Q1 2026.
Castle Biosciences was a new ExodusPoint Capital Management position in Q1 2026.
Castle Biosciences made up 0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1055 holding.
ExodusPoint Capital Management first reported a position in Castle Biosciences in Q2 2020 and has held it in 8 quarters since.
ExodusPoint Capital Management's Castle Biosciences position peaked at $1.55M in Q1 2025.
186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.